Eisai Inc has established Eisai Ltd in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc, Eisai Ltd will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.
"Eisai's entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region," said Hajime Shimizu, chairman and CEO, Eisai Inc. "Most importantly, this new subsidiary will enable Eisai to introduce many of its first-in-class products to people living in Canada who currently do not have access to these treatments, further supporting Eisai's human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide."
Eisai Ltd is working with Health Canada on the approval of select products from the Eisai Inc. portfolio to be introduced in the Canadian market. Over time, additional medicines from Eisai's portfolio of currently marketed products may be introduced to the Canadian market as well as future products from Eisai's pipeline. The company's areas of commercial focus will include neurology, gastrointestinal disorders and oncology/critical care.
Eisai Inc was established in 1995 and is ranked among the top-20 US pharmaceutical companies (based on retail sales).